
Keywords: فعالیت ضد تومور; Cisplatin; Quercetin; Kidney injury; Cytoprotection; Antitumour activity; Rats; ang II; angiotensin II; ANOVA; analysis of variance; AKI; acute kidney injury; C; Control group; CHAPS; 3-((3-cholamidopropyl)dimethylammonio)-1-propanesulfonate; CP; Cisplati